Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer.

Abu Samaan TM, Samec M, Liskova A, Kubatka P, Büsselberg D. · 2019

Read Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer. by Abu Samaan TM, Samec M, Liskova A, Kubatka P, Büsselberg D. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6995578.txt.

Description

Abu Samaan and co-authors review paclitaxel, a flagship chemotherapy drug, in breast cancer care. Their review appeared in Biomolecules. Paclitaxel is among the most widely used anticancer drugs and a first-line choice for breast cancer. It kills cells through several routes that end in programmed death.

Resistance is the central problem. Tumour cells dodge the drug using pump proteins, small regulatory RNAs, and gene mutations. Side effects, including nerve damage and allergic reactions tied to its solvent, add to the burden. A newer albumin-bound form raises efficiency and lowers some risks. Nanoparticle versions aim the drug at tumours for steadier effect. The authors summarise lab and clinical evidence, and judge where this drug's future in breast cancer lies.

Catalog record

CREATORAbu Samaan TM, Samec M, Liskova A, Kubatka P, Büsselberg D.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE85 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6995578

Browse the full library · About the Tower of Babel